In gastric cancer, CMTM3 promotes the degradation of EGFR to impede tumor metastasis (Yuan et al., 2016), indicating that knocking out the CMTM3 gene can be a potential therapy for gastric cancer. This evidence concerns the gene EGFR and gastric cancer.